## Core Concept
Enfuviide, also known as T-20, is an HIV fusion inhibitor used in the treatment of HIV/AIDS. It works by blocking the fusion of the HIV envelope with the host cell membrane. This mechanism is crucial for the entry of the virus into the host cell.

## Why the Correct Answer is Right
Enfuviide (T-20) specifically targets the gp41 subunit of the HIV envelope glycoprotein, preventing the conformational change necessary for fusion. This action inhibits the virus's ability to enter host cells, thereby reducing viral load. Its unique mechanism of action makes it a valuable option for patients with resistance to other antiretroviral therapies.

## Why Each Wrong Option is Incorrect
- **Option A:** Without the specific details of option A, it's challenging to provide a direct explanation. However, if option A describes a characteristic or effect of enfuvirtide that aligns with its known mechanism or clinical use, it would not be incorrect.
- **Option B:** Similarly, without specifics, if option B accurately reflects a property or consequence of using enfuvirtide, it wouldn't be the incorrect statement.
- **Option C:** This option's accuracy depends on its content. If it correctly describes an aspect of enfuvirtide's action, pharmacokinetics, or clinical application, it wouldn't be incorrect.

## Clinical Pearl / High-Yield Fact
A key point to remember about enfuvirtide is that it requires **subcutaneous administration**, which can affect patient compliance and may lead to injection site reactions. This is a critical consideration in the management of HIV patients.

## Correct Answer Line
Given the lack of specific details for each option, the focus remains on the mechanism and clinical use of enfuvirtide. Assuming the correct answer is based on an exception to its characteristics or uses:

**Correct Answer: D.**